Neuroprotective Sirtuin ratio reversed by ApoE4

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 45, 2013, Pages 18303-18308

  Theendakara, Veena ^a   Patent, Alexander ^a   Libeu, Clare A Peters ^a   Philpot, Brittany ^a   Flores, Sonia ^a   Descamps, Olivier ^a   Poksay, Karen S ^a   Zhang, Qiang ^a   Cailing, Gabriellee ^a   Hart, Matthew ^b   John, Varghese ^a   Rao, Rammohan V ^a   Bredesen, Dale E ^a,c  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN ALPHA; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; PROTEIN PRECURSOR; RECOMBINANT PROTEIN; RECOMBINANT SIRTUIN; SIRTUIN 1; SIRTUIN 2; TAU PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEDIATOR; NERVE CELL NETWORK; NEUROPROTECTION; PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BLOTTING, WESTERN; DRUG DISCOVERY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPRECIPITATION; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; SIRTUINS; SURFACE PLASMON RESONANCE; TAU PROTEINS;

EID: 84887314994     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314145110     Document Type: Article

References (29)

1. Bredesen DE, John V (2013) Next generation therapeutics for Alzheimer's disease. EMBO Mol Med 5(6):795-798.
2. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103(15):5644-5651.
3. Harris FM, et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 100(19):10966-10971.
4. Ye S, et al. (2005) Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc Natl Acad Sci USA 102(51):18700-18705.
5. Verghese PB, et al. (2013) ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci USA 110(19):E1807-E1816.
6. Bredesen DE (2009) Neurodegeneration in Alzheimer's disease: Caspases and synaptic element interdependence. Mol Neurodegener 4:27.
7. Olsson A, et al. (2003) Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 183(1):74-80.
8. Donmez G (2013) Sirtuins as possible targets in neurodegenerative diseases. Curr Drug Targets 14(6):644-647.
9. Mahley RW, Weisgraber KH, Huang Y (2009) Apolipoprotein E: Structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 50(Suppl):S183-S188.
10. Libeu CA, Descamps O, Zhang Q, John V, Bredesen DE (2012) Altering APP proteolysis: Increasing sAPPalpha production by targeting dimerization of the APP ectodomain. PLoS ONE 7(6):e40027.
11. Haas C, Cazorla P, Miguel CD, Valdivieso F, Vázquez J (1997) Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein. Biochem J 325(Pt 1):169-175.
12. Qin W, et al. (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281(31):21745-21754.
13. Julien C, et al. (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68(1):48-58.
14. Lee MS, et al. (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163(1):83-95.
15. Liu F, et al. (2003) Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett 547(1-3):193-196.
16. Adalbert R, Gilley J, Coleman MP (2007) Abeta, tau and ApoE4 in Alzheimer's disease: The axonal connection. Trends Mol Med 13(4):135-142.
17. Alonso AD, et al. (2010) Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285(40):30851-30860.
18. Bredesen DE, John V, Galvan V (2010) Importance of the caspase cleavage site in amyloid-β protein precursor. J Alzheimers Dis 22(1):57-63.
19. Endres K, Fahrenholz F (2010) Upregulation of the alpha-secretase ADAM10-risk or reason for hope? FEBS J 277(7):1585-1596.
20. Cedazo-Mínguez A, Wiehager B, Winblad B, Hüttinger M, Cowburn RF (2001) Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem Int 38(7):615-625.
21. Vincent B, Smith JD (2001) Astrocytes down-regulate neuronal beta-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoformspecific manner. Eur J Neurosci 14(2):256-266.
22. Korner S, et al. (2013) Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: Neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis 11(3):141-152.
23. Outeiro TF, et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837):516-519.
24. Yamakuchi M (2012) MicroRNA Regulation of SIRT1. Front Physiol 3:68.
25. Finch CE (2010) Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: Roles of infection, inflammation, and nutrition. Proc Natl Acad Sci USA 107(Suppl 1):1718-1724.
26. Min SW, et al. (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6):953-966.
27. Chang KA, et al. (2006) Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol 26(11):4327-4338.
28. Cvek B, Dvorak Z (2008) The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 13(15-16):716-722.
29. Wen Y, et al. (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28(10):2624-2632.